{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-061346","form_type":"8-K","ticker":"ORGO","cik":"0001661181","company_name":"Organogenesis Holdings Inc.","filed_at":"2022-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.675704+00:00","generated_at":"2026-06-27T03:04:37.873213+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Organogenesis Q4 revenue $128.6M (+20% YoY), FY22 guidance $485M-$515M","bullets":["Q4 net revenue $128.6M (up 20% YoY); Advanced Wound Care $121.4M (+30%), Surgical & Sports Medicine $7.2M (-45%).","Q4 GAAP net income $51.7M ($0.39 diluted EPS) vs $18.3M ($0.15) a year ago; adjusted EBITDA $26.3M.","FY2021 net revenue $468.1M (+38% YoY); net income $94.9M ($0.71 diluted EPS); adjusted EBITDA $89.1M.","FY2022 guidance: net revenue $485M-$515M (+4% to +10% YoY); net income $56.5M-$71.5M; adjusted EBITDA $79.9M-$95.3M.","Cash and equivalents $114.5M; total debt $73.6M as of Dec 31, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-061346","json":"https://secwatch.observer/filing/0001193125-22-061346.json","markdown":"https://secwatch.observer/filing/0001193125-22-061346.md","text":"https://secwatch.observer/filing/0001193125-22-061346.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661181/000119312522061346/0001193125-22-061346-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661181/000119312522061346/d325515d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:04:37.873213+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}